Tiana Raveloarivahy

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

Marc André, T. Girinsky, Massimo Federico et al. · Journal of Clinical Oncology · 2017 · 532 citations · Full text

Medicine, Oncology, Pharmacology +17

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

John Raemaekers, Marc André, Massimo Federico et al. · Journal of Clinical Oncology · 2014 · 383 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Anne‐Ségolène Cottereau, Annibale Versari, Annika Loft et al. · Blood · 2018 · 189 citations · Full text

Medicine, Hematology, Oncology +11

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier et al. · European Journal of Cancer · 2017 · 115 citations

Medicine, Oncology, Pharmacology +10

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Patrick Schöffski, Agnieszka Woźniak, Silvia Stacchiotti et al. · Annals of Oncology · 2017 · 96 citations · Full text

Medicine, Oncology, Pharmacology +8